- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05878184
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
April 3, 2024 updated by: Sana Biotechnology
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single arm, Phase 1, first-in-human (FIH) study to evaluate the safety and tolerability of SC291 administered intravenously (IV) following a standard lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with NHL or CLL who have received two or more prior systemic treatments per standard of care (or after autologous stem cell transplant [ASCT] for NHL).
This study will be conducted in 2 parts.
Phase 1a: dose finding using a 3+3 design in subjects with NHL or CLL.
Phase 1b: dose expansion to further evaluate safety and efficacy at the RP2D in subjects with LBCL and CLL.
Study Type
Interventional
Enrollment (Estimated)
57
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Barbara Metallo
- Email: ardent@sana.com
Study Contact Backup
- Name: Ndidi Onwudiwe
- Phone Number: 206 791 3731
- Email: ardent@sana.com
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Recruiting
- Peter Maccallum Cancer Centre
-
Principal Investigator:
- Philip Thompson, MD
-
Contact:
- Meg Scully
- Email: Meg.scully@petermac.org
-
Contact:
- Felicity McLeay
- Email: felicity.mcleay@petermac.org
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Sylvia Dulan
- Email: sdulan@coh.org
-
Contact:
- Teresa Kim
- Email: teresakim@coh.org
-
Principal Investigator:
- Elizabeth Budde, MD
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford Cancer Institute
-
Principal Investigator:
- Saurabh Dahiya, MD
-
Contact:
- Vivian Leung
- Email: vivian0@stanford.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Northside Hospital
-
Contact:
- Caitlin Guzowski
- Email: caitlin.guzowski@northside.com
-
Principal Investigator:
- Scott Solomon, MD
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Recruiting
- University of Kansas Medical Center
-
Principal Investigator:
- Joseph McGuirk, MD
-
Contact:
- Aleks Kostic
- Email: akostic@kumc.edu
-
Contact:
- Melissa Youngberg
- Email: myoungberg@kumc.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Karmanos Cancer Institute
-
Principal Investigator:
- Abhinav Deol, MD
-
Contact:
- Grace Bae
- Email: baeg@karmanos.org
-
Contact:
- Sarah Park
- Email: parks@karmanos.org
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University Of Nebraska Medical Center
-
Contact:
- Linda Chee
- Email: linda.chee@unmc.edu
-
Contact:
- Susan Blumel
- Email: sblumel@unmc.edu
-
Principal Investigator:
- Matthew Lunning, DO
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Sattva Neelapu, MD
-
Contact:
- Swapna Johncy, MD
- Email: sjjohncy@mdanderson.org
-
Contact:
- Grace Balada
- Email: wgwatson@mdanderson.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female subjects aged 18-80 years at the time of signing informed consent.
- Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria), including:
- Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma), primary mediastinal large -- - B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma grade 3B
- Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)
- Marginal zone lymphoma (dose escalation only)
- Mantle cell lymphoma (dose escalation only)
- CLL or SLL
- Relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant
- ECOG performance status of 0 or 1.
- At least one measurable lesion per Lugano Classification (NHL); CLL subjects must meet iwCLL treatment criteria
- Life expectancy ≥12 weeks
Exclusion Criteria:
- Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell). (Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required)
- History of primary central nervous system (CNS) lymphoma or presence of CNS metastases
- Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)
- Autologous HSCT within 6 weeks of treatment with SC291 (or allogeneic HSCT at any time).
- Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent).
- History or presence of cardiac or CNS disorders as defined in the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SC291 Plus Chemotherapy Regimen
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC291
|
SC291 is an allogeneic CAR-T cell therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate safety and tolerability of SC291
Time Frame: 24 months
|
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate preliminary anti-tumor activity of SC291
Time Frame: 24 months
|
Preliminary anti-tumor activity: Proportion of subjects with an objective response (including partial response or complete response)
|
24 months
|
Evaluate cellular kinetics and persistence of SC291
Time Frame: 24 months
|
Cellular kinetics-related parameters evaluated by CAR T cell copy number
|
24 months
|
Evaluate host immunogenicity to SC291
Time Frame: 24 months
|
Incidence of anti-CD19-directed CAR antibodies
|
24 months
|
Evaluate cellular kinetics and persistence of SC291
Time Frame: 24 months
|
Cellular kinetics related peak (Cmax) in peripheral blood
|
24 months
|
Evaluate cellular kinetics and persistence of SC291
Time Frame: 24 months
|
Area under the concentration time curve (AUC) in peripheral blood
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Paul Brunetta, MD, Sana Biotechnology, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 2, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
April 28, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 26, 2023
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
April 3, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- SC291-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on SC291
-
Sana BiotechnologyRecruitingSystemic Lupus Erythematosus | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Lupus Erythematosus | SLE (Systemic Lupus) | Granulomatous PolyangiitisUnited States